网络元分析比较了不同策略对药物过量使用头痛的疗效
Prut Koonalintip1, Suppakorn Yamutai2, Suwanna Setthawatcharawanich2
1Division of Neurology, Department of Internal Medicine, Prince of Songkla University, Hatyai, Songkhla, Thailand. koo.prut@gmail.com.
The journal of headache and pain
|February 26, 2025
概括
组合疗法,包括神经阻塞和抗CGRP治疗,在药物过量使用头痛 (MOH) 中最有效. 单独的突然戒断不足以管理MOH,但预防策略在减少头痛天数方面表现出类似的有效性.
科学领域:
- 神经学 神经学
- 临床药理学 临床药理学
背景情况:
- 药物过度使用头痛 (MOH) 是一种普遍存在的二次头痛疾病,与频繁的急性药物使用有关.
- 尽管有可用的治疗方法,但MOH的最佳管理策略仍然不确定.
研究的目的:
- 进行网络元分析 (NMA),比较各种MOH管理策略的有效性.
- 主要关注的是减少每月头痛天数.
主要方法:
- 对MOH戒断策略的随机对照试验 (RCT) 的系统审查.
- 使用随机效应NMA模型进行分析,结合直接和间接证据.
- 评估治疗疗效和偏差风险.
主要成果:
- 组合疗法 (例如,口服预防和神经阻塞的戒断;口服预防和抗CGRP疗法限制急性药物治疗) 在减少每月头痛日 (分别为-10.6天和-8.47天) 中表现出最高的疗效.
- 头痛预防策略 (口服预防,抗CGRP疗法,毒素) 显示出显著的降低,但没有单一的策略优越.
- 单独的突然戒断并没有显著的效果 (平均差异为-2.77天).
结论:
- 组合疗法,特别是那些涉及抗CGRP治疗和神经阻塞的组合疗法,对于MOH管理非常有效.
- 虽然各种预防策略具有相似的有效性,但单独突然戒断是不够的.
- 有效的治疗可以减少头痛的频率,降低MOH复发的风险.
相关概念视频
Agonism and Antagonism: Quantification
301
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
301
Dose-Response Relationship: Potency and Efficacy
4.1K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.1K
Analgesia and Pain Management
422
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
422
Antidepressant Drugs: MAOIs and Other Agents
176
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
176
Opioid Analgesics: Synthetic and Semisynthetic Opioids
204
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
204
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
370
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
370


